Loading clinical trials...

Influence of Adiposity on IGF-1 and Fitness Response to Exercise in Cancer Survivors | Clinical Trials | Clareo Health

COMPLETEDNA

Influence of Adiposity on IGF-1 and Fitness Response to Exercise in Cancer Survivors

The Influence of Excess Adiposity on Cardiorespiratory, Insulin-like Growth Factor, and Metabolic Responses to a Standardized Aerobic Exercise Program in Cancer Survivors

NCT05558384•University of Colorado, Denver

View on ClinicalTrials.gov

Summary

This is a pilot feasibility study of an investigation of the influence of excess adiposity on cardiorespiratory fitness (CRF), insulin-like growth factor-1 (IGF-1), and metabolic responses to a standardized aerobic exercise program in cancer survivors. This investigation attempts to isolate the influence of adiposity on these responses. We will enroll overweight, obese, and normal weight cancer survivors with a primary diagnosis of breast, prostate, or colorectal cancer who have completed all cancer-related treatment. Participants will engage in a 15-week aerobic exercise intervention with pre- and post-intervention assessments.

Eligibility

Age

21 - 79 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Primary cancer diagnosis of breast, prostate, or colorectal cancer
•Completion of all cancer-related treatment \> than 6 months prior and \< 5 years prior to enrollment
•Ability and willingness to participate in a supervised exercise program
•* All participants will be required to obtain a signed physician clearance to participate in exercise form prior to enrollment

Exclusion Criteria

•Presence of a secondary active cancer diagnosis or metastatic disease
•Any current cancer treatment (including hormonal treatment) or planned cancer treatment in the next 5 months
•Greater than 100 min of self-reported regular exercise per week
•BMI \< 18.5 (underweight)
•Any significant metabolic condition, such as diabetes. Individuals with pre-diabetes or metabolic syndrome will not be excluded, but this information will be recorded.
•Any medical condition that would impact the safety of, or participation in, an exercise program or exercise testing, including:
•* Orthopedic conditions such as advanced osteoarthritis, mobility-limiting amputations or chronic injuries, or mobility-limiting acute orthopedic injuries
•* Advanced rheumatoid arthritis or chronic widespread pain conditions such as fibromyalgia
•* Pulmonary conditions such as chronic obstructive pulmonary disease, emphysema, or interstitial lung disease
•* Known cardiovascular disease, uncontrolled hypertension, or new cardiac event within the past 6 months

Locations (1)

University of Colorado Hospital

Aurora, Colorado, United States

Key Dates

Start Date

March 22, 2023

Primary Completion Date

October 1, 2024

Completion Date

October 1, 2024

Last Updated

February 24, 2025

Enrollment

ACTUAL participants

Conditions

CancerOverweight and Obesity

Interventions

Aerobic Exercise

BEHAVIORAL

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

NCT05673200

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+2 more

View study

RECRUITINGPHASE1

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

NCT05039801

Advanced Endometrial CarcinomaAdvanced Head and Neck Squamous Cell Carcinoma+36 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 24, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Influence of Adiposity on IGF-1 and Fitness Response to Exercise in Cancer Survivors

Inclusion Criteria

Exclusion Criteria

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers